Skip to content

Saxenda vs Wegovy: daily or weekly, approved uses, cost and coverage

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Saxenda vs Wegovy compares a daily injection with a weekly one. Saxenda (liraglutide) and Wegovy (semaglutide) are both approved for long-term weight reduction, and Wegovy also comes as a daily pill. Novo Nordisk has announced Saxenda will be discontinued. Wegovy self-pay runs from $149 to $399 a month through NovoCare Pharmacy. Saxenda's list price is $1,349.02.

Source: NovoCare self-pay

Key takeaways

  • Novo Nordisk has announced Saxenda will be discontinued, with last shipments to wholesalers in late January 2027.
  • Both are approved for long-term weight reduction. Only Wegovy's label adds cardiovascular and, for the injection, MASH uses.
  • Saxenda is injected every day. Wegovy is injected once a week or taken as a daily tablet.
  • Paying cash? Wegovy through NovoCare runs $149 to $399 a month. Saxenda's list price is $1,349.02.
  • No label converts Saxenda 3 mg to a Wegovy dose. Your prescriber chooses the starting point and timing.

Saxenda vs Wegovy, side by side

From each FDA label and our verified price records
SaxendaWegovy
Active ingredientliraglutidesemaglutide
MakerNovo NordiskNovo Nordisk
FDA-approved uses
  • Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity
  • Reduce excess body weight and maintain weight reduction long term in adults with overweight in the presence of at least one weight-related comorbid condition
  • Reduce the risk of major adverse cardiovascular events in adults with established CV disease and either obesity or overweight (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity (injection)
  • Reduce excess body weight and maintain weight reduction long term in adults with overweight and at least one weight-related comorbid condition (injection and tablets)
  • Reduce excess body weight and maintain weight reduction long term in adults with obesity (tablets)
  • Treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults, under accelerated approval (injection)
How it is takendaily (multi-dose pen)weekly (single-dose pen); daily (tablet)
Strengths0.6 to 3 mg0.25 to 25 mg
Label starting dose
  • 0.6 mg daily
  • 0.25 mg weekly
  • 1.5 mg daily
Cheapest verified self-payNo self-pay price listed$299 per fill at 25 mg
NovoCare self-pay
With covering commercial insuranceNo savings-card price listed$25 with the manufacturer card
Medicare GLP-1 BridgeNoYes: Single-dose pen (7.2 mg pen is branded WEGOVY HD); Tablet (once daily)
LabelRevised: 6/2026 (DailyMed version 22)Revised: 6/2026 (DailyMed version 19)
Saxenda: most common reactions on the label · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionSaxendaPlacebo
Nausea39.3%13.8%
Diarrhea20.9%9.9%
Constipation19.4%8.5%
Vomiting15.7%3.9%
Injection Site Reaction13.9%10.5%
Headache13.6%12.6%
Wegovy: most common reactions on the label · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionWegovy injection 2.4 mg once weeklyPlacebo
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%
Abdominal Pain20%10%
Headache14%10%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Saxenda and Wegovy come from the same company and are approved for the same core purpose, long-term weight reduction. Saxenda is liraglutide, injected every day. Wegovy is semaglutide, injected once a week or swallowed once a day. They aren’t the same medicine, and the comparison has a practical edge, because Novo Nordisk has announced that Saxenda will be discontinued. Everything here follows the FDA labels (Revised: 6/2026 (DailyMed version 22) for Saxenda, Revised: 6/2026 (DailyMed version 19) for Wegovy) and our price records.

Saxenda or Wegovy: which suits whom?

  • You’re starting treatment and want a medicine that isn’t being discontinued. Wegovy has self-pay prices, a savings offer, a place in the Medicare GLP-1 Bridge, a pill form, and no announced end date.
  • You’re already settled on Saxenda, you tolerate it and you have coverage. You can stay on it for as long as supply lasts, if your prescriber agrees. Novo Nordisk has announced last shipments to wholesalers in late January 2027.
  • Daily injections are a burden. Wegovy’s pen is weekly. If any injection is a burden, Wegovy has tablets.
  • You need the cardiovascular or MASH use. Only Wegovy’s label has them.
  • The patient is a teenager. Both labels include patients aged 12 and older with obesity. Saxenda’s adds a body weight above 60 kg.

We make no claim about which produces more weight reduction. If you take Saxenda now, the useful questions for your prescriber are when to plan a change, what comes next, and what your plan will pay for.

What is each approved for?

Both labels approve long-term weight reduction in adults with obesity, and in adults with overweight who have at least one weight-related condition.

For younger patients, Saxenda is approved from age 12 in those with obesity and body weight greater than 60 kg. Wegovy injection is approved from age 12 in those with obesity. Wegovy tablets are for adults.

Wegovy’s label goes further in two directions. Both the injection and the tablets are approved to reduce major adverse cardiovascular events (serious heart and blood vessel events) in adults with established cardiovascular disease and either obesity or overweight. The injection is also approved, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis. Saxenda has neither use.

Daily versus weekly: how are they taken?

Saxenda is one injection every day, at any time of day, without regard to meals. One pen does every dose. Each pen contains 18 mg of liraglutide and is dialed to the dose you’re on, so a pen provides six daily doses at 3 mg. Pen needles aren’t included, and the pen is thrown away 30 days after first use, even if medicine is left.

Wegovy injection is one injection a week, on the same day each week, with or without meals. Each pen is a single dose in a fixed strength and is used one time only. A carton holds four pens, which is 28 days.

Wegovy tablets are taken once a day in the morning on an empty stomach, which swaps the needle for a routine.

How do the dose schedules compare?

The two medicines climb at very different speeds.

Saxenda (0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg) moves up every week: 0.6 mg daily in week 1, then 1.2 mg, 1.8 mg and 2.4 mg, reaching 3 mg daily from week 5. For adults, 3 mg is the recommended dosage, and the lower doses are only for stepping up.

The Wegovy pen (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg) moves up every 4 weeks: 0.25 mg once weekly for weeks 1 through 4, then 0.5 mg, 1 mg and 1.7 mg, reaching the usual maintenance dosage (the dose you stay on) of 2.4 mg from week 17. For weight reduction in adults, 7.2 mg is an optional further step after at least 4 weeks on 2.4 mg.

Wegovy tablets (1.5 mg, 4 mg, 9 mg, 25 mg) step up every 30 days to the 25 mg maintenance dosage from day 91.

Milligrams of liraglutide and of semaglutide aren’t interchangeable, and neither label matches one drug’s dose to the other’s.

Two Saxenda rules have no Wegovy counterpart:

  • A 16-week checkpoint. Adults who haven’t lost at least 4% of their baseline body weight 16 weeks after starting Saxenda should stop it.
  • A short restart window. If more than 3 days pass since the last Saxenda dose, the label says to restart at 0.6 mg daily and climb the schedule again.

The missed dose tool and the titration schedule tool cover both medicines.

What does each cost?

Saxenda. One price: the list price (the full price before any discount) of $1,349.02, taken from Novo Nordisk’s page. Novo Nordisk states that figure without naming the supply period it covers. The Saxenda savings offer closed to new enrollees on June 30, 2023.

Wegovy:

  • Pen, self-pay through NovoCare Pharmacy: $349 a month for 1 mg, 1.7 mg and 2.4 mg, and $399 for the 7.2 mg pen. If you’re new to the offer, you pay $199 a month for up to two fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349.
  • Tablets, self-pay: $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg.
  • Savings offer with commercial insurance that covers Wegovy: as little as $25 a month.
  • List price: $1,349.02 per package.

If your plan doesn’t cover Saxenda, ask your pharmacy for its cash price and set it against the Wegovy figures above. The Saxenda cost page, the Wegovy cost page and the cost calculator take this further.

Does insurance or Medicare cover them?

Commercial plans vary widely on weight-management medicines. Some cover one of these with prior authorization (the plan’s approval before it pays), and some cover neither. With Saxenda’s discontinuation announced, it’s worth asking your plan two questions in one call: whether Saxenda is covered now, and which weight-management medicines will be on the formulary (the plan’s list of covered drugs) next year.

On Medicare, the two part ways. The Part D statute excludes agents when used for weight loss, and CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication.

  • Saxenda has only weight-reduction uses, so it has no other use to qualify under, and it isn’t among the products in the Medicare GLP-1 Bridge.
  • Wegovy is in the Bridge: eligible Part D patients pay a $50 copay per one-month supply of the pen or tablets through December 31, 2027. Separately, CMS names Wegovy prescribed to reduce cardiovascular risk as a use Part D can cover.

Check your own case with the Bridge eligibility checker, and see does Medicare cover Wegovy.

How do the side effects compare?

Both labels are led by gastrointestinal (stomach and bowel) reactions. Each set of figures comes from that medicine’s own adult trials, with different designs and lengths, so they aren’t ranked against each other here.

Saxenda. In the label’s adult trials, nausea was reported by 39.3 percent of patients on Saxenda and 13.8 percent on placebo, diarrhea by 20.9 percent (placebo 9.9 percent), constipation by 19.4 percent (placebo 8.5 percent) and vomiting by 15.7 percent (placebo 3.9 percent). In those trials, 9.8% of patients on Saxenda and 4.3% on placebo stopped treatment early because of adverse reactions.

Wegovy. In the adult weight-reduction trials of the 2.4 mg injection, nausea was reported by 44 percent of patients (16 percent on placebo), diarrhea by 30 percent (16 percent), vomiting by 24 percent (6 percent) and constipation by 24 percent (11 percent). In those trials, 6.8% of patients on Wegovy and 3.2% on placebo permanently stopped treatment because of adverse reactions.

Both carry a boxed warning about thyroid C-cell tumors. Neither should be used by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or with MEN 2 (an inherited condition linked to it). Both labels also warn about an increase in heart rate, acute pancreatitis (inflammation of the pancreas) and gallbladder disease.

Can you switch from Saxenda to Wegovy?

With Saxenda leaving the market, this is the question many readers actually have. The labels offer little. The Wegovy label has switching instructions only between its own pen and tablets. What it does state is its starting dosage, 0.25 mg once weekly for the injection and 1.5 mg once daily for the tablets, and that using Wegovy with any other GLP-1 receptor agonist isn’t recommended.

No label converts 3 mg of Saxenda to any Wegovy dose, and we don’t supply a conversion. Your prescriber chooses the starting point and the timing.

Our guide to moving from Saxenda to Wegovy covers the steps, and the switching planner shows the label text. If your prescriber is also considering tirzepatide, read Saxenda vs Zepbound. Every other pairing is on the comparison hub.

Frequently asked questions

What is the difference between Saxenda and Wegovy?

Saxenda is liraglutide, injected once a day from a pen you dial. Wegovy is semaglutide, injected once a week from a single-dose pen or taken as a daily tablet. Both are Novo Nordisk medicines approved for long-term weight reduction. Wegovy's label adds a cardiovascular use and, for the injection, MASH. Novo Nordisk has announced that Saxenda will be discontinued.

Is Saxenda cheaper than Wegovy?

Saxenda's list price is $1,349.02. Wegovy has self-pay prices through NovoCare Pharmacy: $349 a month for the 1 mg, 1.7 mg and 2.4 mg pens, and from $149 a month for the tablets.

Can I switch from Saxenda to Wegovy?

A prescriber can move you from one to the other, but the labels give no conversion. The Wegovy label states its starting dosage, 0.25 mg once weekly for the injection, and says Wegovy shouldn't be used together with any other GLP-1 receptor agonist. Your prescriber decides where you start and when.

Is Saxenda being discontinued?

Yes, according to Novo Nordisk, which has announced that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027. If you take Saxenda, talk with your prescriber about what comes next well before then.

Does Medicare cover Saxenda or Wegovy?

CMS says Medicare generally does not cover GLP-1 drugs for the weight loss indication, and Saxenda's approved uses are all weight reduction. Wegovy has two routes: the Medicare GLP-1 Bridge, at a $50 monthly copay for eligible Part D patients, and Part D itself when Wegovy is prescribed to reduce cardiovascular risk. Saxenda isn't in the Bridge.

Sources (21)

  1. 1.
    FDA label (DailyMed): Saxenda prescribing information, section 2.1
    “Inject SAXENDA subcutaneously once daily at any time of day, without regard to the timing of meals.”
  2. 2.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “It contains 18 mg of liraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3 mg.”
  3. 3.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “Your pen is made to be used with disposable needles up to a length of 8 mm. Pen needles are not included with your Saxenda pen.”
  4. 4.
    FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
    “The Saxenda pen you are using should be thrown away after 30 days, even if it still has Saxenda left in it.”
  5. 5.
    FDA label (DailyMed): Saxenda prescribing information, section 2.1
    “If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
  6. 6.
    FDA label (DailyMed): Saxenda prescribing information, section 2.2
    “Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
  7. 7.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  8. 8.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
  9. 9.
    FDA label (DailyMed): Wegovy prescribing information, Instructions for Use (single-dose pen)
    “Your WEGOVY pen is for 1 time use only. The WEGOVY pen is for subcutaneous (under the skin) use only.”
  10. 10.
    FDA label (DailyMed): Wegovy prescribing information, section 16
    “WEGOVY injection is a clear, colorless solution available in cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch) as follows:”
  11. 11.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  12. 12.
    FDA label (DailyMed): Wegovy prescribing information, section 4
    “a personal or family history of MTC or in patients with MEN 2”
  13. 13.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
  14. 14.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  15. 15.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.